全文获取类型
收费全文 | 22810篇 |
免费 | 2098篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 219篇 |
儿科学 | 611篇 |
妇产科学 | 580篇 |
基础医学 | 2686篇 |
口腔科学 | 403篇 |
临床医学 | 2326篇 |
内科学 | 4672篇 |
皮肤病学 | 384篇 |
神经病学 | 2166篇 |
特种医学 | 780篇 |
外国民族医学 | 3篇 |
外科学 | 3417篇 |
综合类 | 509篇 |
一般理论 | 43篇 |
预防医学 | 2479篇 |
眼科学 | 309篇 |
药学 | 1538篇 |
中国医学 | 30篇 |
肿瘤学 | 1776篇 |
出版年
2021年 | 350篇 |
2020年 | 201篇 |
2019年 | 396篇 |
2018年 | 497篇 |
2017年 | 342篇 |
2016年 | 315篇 |
2015年 | 405篇 |
2014年 | 564篇 |
2013年 | 838篇 |
2012年 | 1156篇 |
2011年 | 1188篇 |
2010年 | 738篇 |
2009年 | 658篇 |
2008年 | 1107篇 |
2007年 | 1194篇 |
2006年 | 1196篇 |
2005年 | 1164篇 |
2004年 | 1066篇 |
2003年 | 993篇 |
2002年 | 912篇 |
2001年 | 599篇 |
2000年 | 630篇 |
1999年 | 571篇 |
1998年 | 290篇 |
1997年 | 214篇 |
1996年 | 223篇 |
1995年 | 237篇 |
1994年 | 180篇 |
1993年 | 170篇 |
1992年 | 422篇 |
1991年 | 409篇 |
1990年 | 356篇 |
1989年 | 367篇 |
1988年 | 329篇 |
1987年 | 317篇 |
1986年 | 288篇 |
1985年 | 304篇 |
1984年 | 258篇 |
1983年 | 219篇 |
1982年 | 171篇 |
1981年 | 147篇 |
1979年 | 240篇 |
1978年 | 174篇 |
1977年 | 143篇 |
1975年 | 139篇 |
1974年 | 150篇 |
1973年 | 190篇 |
1972年 | 186篇 |
1971年 | 158篇 |
1969年 | 147篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
951.
952.
Sickle cell disease (SCD) is associated with an increased risk of vascular-occlusive events and of leukemia. Clonal hematopoiesis (CH) may increase both risks. In turn, physiologic abnormalities in SCD may modify the incidence and/or distribution of genetic alterations in CH. In a recent issue of the JCI, Liggett et al. found no difference in CH rate between individuals with versus without SCD. Here we contextualize this report and discuss the complex interplay between CH and SCD with particular attention to consequences for emerging gene therapies. We further consider the limitations in our current understanding of these topics that must be addressed in order to optimize therapeutic strategies for SCD. 相似文献
953.
954.
Skin metastases from transitional cell bladder cancer 总被引:1,自引:0,他引:1
Three cases of transitional cell bladder cancer metastatic to skin are described. This manifestation of transitional cell uroepithelial malignancy was previously believed to be quite uncommon. The authors' experience suggests that this occurrence is not that rare and that it may reflect increased longevity in successfully treated patients, allowing previously unusual manifestations of metastatic disease to become evident. The role of aspiration skin biopsy is discussed. 相似文献
955.
Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy 总被引:14,自引:0,他引:14
Cohen LF Breslin TM Kuerer HM Ross MI Hunt KK Sahin AA 《The American journal of surgical pathology》2000,24(9):1266-1272
Sentinel lymph node (SLN) biopsy has been shown to predict axillary metastases accurately in early stage breast cancer. Some patients with locally advanced breast cancer receive preoperative (neoadjuvant) chemotherapy, which may alter lymphatic drainage and lymph node structure. In this study, we examined the feasibility and accuracy of SLN mapping in these patients and whether serial sectioning and keratin immunohistochemical (IHC) staining would improve the identification of metastases in lymph nodes with chemotherapy-induced changes. Thirty-eight patients with stage II or III breast cancer treated with neoadjuvant chemotherapy were included. In all patients, SLN biopsy was attempted, and immediately afterward, axillary lymph node dissection was performed. If the result of the SLN biopsy was negative on initial hematoxylin and eosin-stained sections, all axillary nodes were examined with three additional hematoxylin and eosin sections and one keratin IHC stain. SLNs were identified in 31 (82%) of 38 patients. The SLN accurately predicted axillary status in 28 (90%) of 31 patients (three false negatives). On examination of the original hematoxylin and eosin-stained sections, 20 patients were found to have tumor-free SLNs. With the additional sections, 4 (20%) of these 20 patients were found to have occult lymph node metastases. These metastatic foci were seen on the hematoxylin and eosin staining and keratin IHC staining. Our findings indicate that lymph node mapping in patients with breast cancer treated with neoadjuvant chemotherapy can identify the SLN, and SLN biopsy in this group accurately predicts axillary nodal status in most patients. Furthermore, serial sectioning and IHC staining aid in the identification of occult micrometastases in lymph nodes with chemotherapy-induced changes. 相似文献
956.
Arellano R Gan BS Salpeter MJ Yeo E McCluskey S Pinto R Irish J Ross DC Doyle DJ Parkin J Brown D Rotstein L Witterick I Matthews W Yoo J Neligan PC Gullane P Lampe H 《Anesthesia and analgesia》2005,100(6):1846-1853
In Canada, hydroxyethyl starch 264/0.45 (HES 264/0.45; molar weight 264 kDa, molar substitution 0.45) has largely replaced albumin as the colloidal fluid of choice for perioperative intravascular volume expansion. The maximum recommended dose of HES 264/0.45 is 28 mL/kg; however, there are no clinical data supporting this limit. In this study we compared the hemostatic effects of HES 264/0.45 versus 5% albumin in doses up to 45 mL/kg over 24 h during major reconstructive head and neck surgery. Fifty patients were randomized to receive HES 264/0.45 or 5% human albumin from the induction of anesthesia until 24 h thereafter. Both albumin and HES 264/0.45 effectively maintained physiologic variables in the perioperative and postoperative periods. The partial thromboplastin time and international normalized ratio were significantly increased in the HES 264/0.45 group compared with the albumin group after infusion of 30 mL/kg and 45 mL/kg (P < 0.05). Factor VIII activity and von Willebrand factor level were significantly reduced in the HES 264/0.45 group compared with the albumin group after infusion of 15 mL/kg, 30 mL/kg, and 45 mL/kg (P < 0.05). Significantly more subjects in the HES 264/0.45 group received allogeneic red blood cell transfusions (P < 0.02). We conclude that HES 264/0.45 infusions >30 mL/kg over 24 h impair coagulation to a greater extent than albumin, possibly leading to more allogeneic transfusions. 相似文献
957.
Managing Osteoporosis in Patients on Long‐Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research 下载免费PDF全文
Robert A Adler Ghada El‐Hajj Fuleihan Douglas C Bauer Pauline M Camacho Bart L Clarke Gregory A Clines Juliet E Compston Matthew T Drake Beatrice J Edwards Murray J Favus Susan L Greenspan Ross McKinney Jr Robert J Pignolo Deborah E Sellmeyer 《Journal of bone and mineral research》2016,31(10):1910-1910
958.
Incidence and Impact of Documented Eradication of Breast Cancer Axillary Lymph Node Metastases Before Surgery in Patients Treated With Neoadjuvant Chemotherapy 总被引:11,自引:0,他引:11
Henry M. Kuerer Aysegul A. Sahin Kelly K. Hunt Lisa A. Newman Tara M. Breslin Fred C. Ames Merrick I. Ross Aman U. Buzdar Gabriel N. Hortobagyi S. Eva Singletary 《Annals of surgery》1999,230(1):72-78
OBJECTIVE: To determine the incidence and prognostic significance of documented eradication of breast cancer axillary lymph node (ALN) metastases after neoadjuvant chemotherapy. SUMMARY BACKGROUND DATA: Neoadjuvant chemotherapy is the standard of care for patients with locally advanced breast cancer and is being evaluated in patients with earlier-stage operable disease. METHODS: One hundred ninety-one patients with locally advanced breast cancer and cytologically documented ALN metastases were treated in two prospective trials of doxorubicin-based neoadjuvant chemotherapy. Patients had breast surgery with level I and II axillary dissection followed by additional chemotherapy and radiation treatment. Nodal sections from 43 patients who were originally identified as having negative ALNs at surgery were reevaluated and histologically confirmed to be without metastases. An additional 1112 sections from these lymph node blocks were obtained; half were stained with an anticytokeratin antibody cocktail and analyzed. Survival was calculated using the Kaplan-Meier method. RESULTS: Of 191 patients with positive ALNs at diagnosis, 23% (43 patients) were converted to a negative axillary nodal status on histologic examination (median number of nodes removed = 16). Of the 43 patients with complete axillary conversion, 26% (n = 11) had N1 disease and 74% (n = 32) had N2 disease. On univariate analysis, patients with complete versus incomplete histologic axillary conversion were more likely to have initial estrogen-receptor-negative tumors, smaller primary tumors, and a complete pathologic response in the primary tumor. The 5-year disease-free survival rates were 87% in patients with preoperative eradication of axillary metastases and 51% for patients with residual nodal disease after neoadjuvant chemotherapy. Of the 39 patients with complete histologic conversion for whom nodal blocks were available, occult nodal metastases were found in additional nodal sections in 4 patients (10%). At a median follow-up of 61 months, the 5-year disease-free survival rates were 87% in patients without occult nodal metastases and 75% in patients with occult nodal metastases. CONCLUSIONS: Neoadjuvant chemotherapy can completely clear the axilla of microscopic disease before surgery, and occult metastases are found in only 10% of patients with a histologically negative axilla. The results of this study have implications for the potential use of sentinel lymph node biopsy as an alternative to axillary dissection in patients treated with neoadjuvant chemotherapy. 相似文献
959.
960.
B. Lees S. W. Garland C. Walton D. Ross M. I. Whitehead J. C. Stevenson 《Osteoporosis international》1996,6(6):480-485
We have performed a 2-year prospective double-masked study to determine whether the bisphosphonate pamidronate can prevent bone loss in postmenopausal women and its optimal dosage regimen. One hundred and twenty-one such women (mean ± SD age 57.6±3.4 years; mean ± SD time since menopause 7.5±3.5 years) were randomized to receive either oral pamidronate (300 mg/day) for 4 weeks every 4 months (group A), oral pamidronate (150 mg/day) for 4 weeks every 2 months (group B) or identical placebo capsules (group C). Bone mineral density (BMD) measurements at the lumbar spine and proximal femur were performed at baseline and at 6-month intervals for 2 years using dual-energy X-ray absorptiometry. BMD at the lumbar spine (L2–4) increased significantly in groups A and B after 2 years of treatment (mean ± SD 2.8±2.1% and 3.0±2.9% respectively, bothp<0.001) but decreased in the placebo group (–1.6±3.1%,p<0.01). Identical results were seen for BMD at the femoral neck, which increased significantly in groups A and B after 2 years of treatment (1.2±2.3% and 1.3±2.9% respectively, bothp<0.05) but decreased in the placebo group (–1.9±3.9%,p<0.05). There were significant differences over 2 years between the groups at all anatomical sites (lumbar spine, femoral neck and trochanteric region, allp<0.001; Ward's triangle,p<0.01). However, there were no significant differences between groups A and B, suggesting that the two treatment regimens were equally effective in conserving BMD. There were, however, marked differences in tolerability between the two treatment regimens: 13 women (34%) in group A withdrew from the study because of side-effects, but only 5 women (12%) in group B, which was comparable with placebo. These data demonstrate that intermittent oral pamidronate will prevent bone loss from the lumbar spine and proximal femur of postmenopausal women, and that the more frequent but lower dose regimen is well tolerated. 相似文献